NEW YORK, Feb. 14, 2020 /PRNewswire/ --
The global HPV testing market is expected to grow at a CAGR of
over 12% during the period 2019–2025.
Read the full report:
https://www.reportlinker.com/p05862330/?utm_source=PRN
The following factors are likely to contribute to the growth of
the HPV testing market during the forecast period:
• Increasing Prevalence of HPV Infections
• Emergence of Point-of-care Diagnostics/Rapid HPV Tests
• Rise of mRNA Test for Cervical Cancer Screening
• Increasing Demand for HPV Co-testing
The increased procurement of the latest-generation HPV testing
analyzers and test kits, coupled with the high prevalence of
HPV-related infections and cancers, especially cervical and
vaginal, influences the growth of the global HPV testing market.
Traditionally, cervical cancer screening was based on cervical
cytology. However, in recent years, several countries and global
health bodies have recommended the inclusion of HPV tests for
cervical and pre-cancer screening programs, which is likely to
boost the market.
The demand for new innovative testing consumables and instruments
using advanced techniques such as the HPV mRNA test, which promotes
accurate and sensitive diagnostic outcomes, is driving the market
growth. Further, with the availability of positive clinical
evidence, demonstrating the superiority of the latest generation
advanced testing devices, end-users will become increasingly aware
of clinical benefits and rapidly adopt these tests as an essential
screening tool for cervical cancer screening. Therefore, the
improvement in patient management, favorable government initiatives
for primary screening, and the rising awareness of advanced testing
in developed and developing economies are increasing the adoption
globally.
The study considers the present scenario of the HPV testing market
and its market dynamics for the period 2019?2025. It covers a
detailed overview of several market growth enablers, restraints,
and trends. The study offers both the demand and supply aspects of
the market. It profiles and examines leading companies and other
prominent companies operating in the market.
HPV Testing Market: Segmentation
This research report includes detailed segmentation by products,
applications, end-user, and geography. The consumables segment is
growing due to the high adoption of advanced testing kits,
reagents, and other related consumables to detect and screen
cervical cancers globally. The segment is also growing at a fast
rate due to the recurring purchase by end-users to perform HPV
tests. These screening tests are likely to gain wide acceptance in
emerging economies due to favorable government initiatives and the
rise in consumer spending power. Therefore, market players are
focusing on significant product launches in a low resource setting
of emerging countries, thereby accelerating the segment growth. The
instruments segment is growing at a slow pace as the procurement of
analyzers is capital intensive and the purchasing decision depends
on financial resources and budget allocations. However, the
increasing availability of automated and compact
analyzers/instruments has significantly improved the efficiency and
quality of end-user operations. Automation and integration of
several diagnostic platforms have led to the introduction of
innovative diagnostic analyzers, thereby driving the growth during
the forecast period.
The cervical application segment is growing on account of the rise
in cervical cancer incidences. The increased focus of market
players to launch screening products in low resource countries is
expected to drive the cervical application segment during the
upcoming years. HPV self-sampling is emerging with the rapid
availability of these devices as a potential screening strategy,
especially in the US, which is likely to contribute to the
growth.
The application of HPV testing for vaginal cancer offers powerful
negative predictive values. Therefore, the detection of infection
with a high-risk HPV, which produce visible signs, is a powerful
tool for vaginal cancer screening. Owing to the benefit of HPV
testing, coupled with the rise in the vaginal cancer burden
globally, vendors are offering innovative testing devices, which
are driving the growth of the vaginal application segment.
The increased focus on enhancing the sensitivity of cervical
screening to reduce false-negative diagnoses as well as improve the
specificity of molecular tests to detect high-risk human
papillomavirus is a major factor contributing to the growth of
standard reference laboratories. The availability of standard
reference laboratory services for the evaluation of HPV DNA and
antibody detection in biological specimens through
capacity-building worldwide is another reason for the growth of
standard reference laboratories.
Healthcare professionals in hospitals use human papillomavirus
testing as a screening procedure for the cervical and other related
cancers. The market is likely to grow at a fast pace during the
forecast period on account of the adoption of advanced testing
products. A majority of patients with high-risk symptoms prefer
visiting hospitals for diagnosis due to advanced infrastructure
facilities available in major private and public hospitals.
The physicians' office and clinic segment is expected to grow
mainly on account of the growing prevalence of cervical cancers
worldwide. These clinics perform laboratory screening through
private offices for people with a high risk of cervical and other
HPV associated cancers at an affordable cost. Another factor
responsible for the rise of this segment is the availability of
super-specialty expertise in these clinics.
Market Segmentation by Products
• Consumables
• Instruments
Market Segmentation by Applications
• Cervical Cancers
• Vaginal Cancers
• Others
Market Segmentation by End-user
• Standard Reference Laboratories
• Hospitals
• Physicians' Office and Clinics
Insights by Geography
North America is growing at a
significant rate due to the growing preference for HPV tests to
detect and screen cervical cancers and other related infections.
The presence of a large pool of population with a high risk of
developing cervical cancer, the increasing acceptance of HPV
testing, and growing awareness of advanced testing procedures have
accelerated the market.
Germany, France, the UK, Spain, and Italy are the leading contributors to the
Europe market. The presence of
highly sophisticated healthcare infrastructure, a high awareness
level of advanced HPV screening procedures with high analytic
sensitivity for detecting cervical cancers, and increased
investment in R&D activities are the major drivers for the
growth in the region.
The region has the largest population density and the highest
population with a high risk of developing cervical cancers and
other associated infections. Japan, China,
Australia, South Korea, and India are the major revenue contributors from
the region. Japan is the major
revenue contributor to the HPV testing market in APAC due to
advancements in healthcare infrastructure, the rise in healthcare
expenditure, and favorable public and private initiatives for an
increase in the healthcare access.
Market Segmentation by Geography
• North America
o US
o Canada
• Europe
o Germany
o France
o UK
o Spain
o Italy
• APAC
o Japan
o China
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
o Argentina
• MEA
o Turkey
o South Africa
o Saudi Arabia
Insights by Vendors
The global HPV testing market is highly competitive and
characterized by the presence of several global, regional, and
local players. F. Hoffmann-La Roche, QIAGEN, Hologic, and Abbott
are the dominant players, and their testing instruments and
consumables are widely used by end-users globally. These companies
have a wide geographic footprint, diversified product portfolio,
and a strong focus on innovation and research activities. Over the
years, these players have been dominating the market as they have
introduced safe and efficient products in the market. Vendors,
especially global players, are increasingly focusing on pursuing
inorganic growth strategies such as acquisitions and strategic
partnerships to expand their presence, enhance product portfolio,
and improve expertise in the market.
Key Vendors
• Hoffmann-La Roche
• QIAGEN
• Hologic
• Abbott
Other Vendors
• Arbor Vita
• BD
• Cepheid
• DAAN Gene
• DiaCarta
• Fujirebio
• Greiner Bio One International
• Hybribio
• IncellDx
• Norgen Biotek
• PreTect
• Seegene
• Siemens Healthineers
• Takara Bio
• Xiamen Zeesan Biotech
• ZYTOVISION
Key Market Insights
The analysis of the global HPV testing market provides sizing and
growth opportunities for the forecast period 2020–2025.
• Offers sizing and growth prospects of the market for the forecast
period 2020–2025.
• Provides comprehensive insights on the latest industry trends,
forecast, and growth drivers in the market.
• Includes a detailed analysis of growth drivers, challenges, and
investment opportunities.
• Delivers a complete overview of segments and the regional outlook
of the market.
• Offers an exhaustive summary of the vendor landscape, competitive
analysis, and key strategies to gain competitive advantage.
Read the full report:
https://www.reportlinker.com/p05862330/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/the-global-hpv-testing-market-is-expected-to-grow-at-a-cagr-of-over-12-during-the-period-20192025-301005146.html
SOURCE Reportlinker